Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial
Conferences
Karukonda, P; Czito, BG; Duffy, E; Uronis, HE; D'Amico, TA; Strickler, JH; Niedzwiecki, D; Willett, C; Palta, M
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Karukonda, P., Czito, B. G., Duffy, E., Uronis, H. E., D’Amico, T. A., Strickler, J. H., … Palta, M. (2023). Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Karukonda, Pooja, Brian G. Czito, Eileen Duffy, Hope Elizabeth Uronis, Thomas A. D’Amico, John H. Strickler, Donna Niedzwiecki, Christopher Willett, and Manisha Palta. “Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Karukonda P, Czito BG, Duffy E, Uronis HE, D’Amico TA, Strickler JH, et al. Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Karukonda, Pooja, et al. “Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Karukonda P, Czito BG, Duffy E, Uronis HE, D’Amico TA, Strickler JH, Niedzwiecki D, Willett C, Palta M. Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis